Scientistscan now connect company-approved AI providers such as Claude Code and GitHubCopilot directly to Flare, helping teams set up, execute, and analyze complexcomputational chemistry workflows in minutes not hours.
CAMBRIDGE, UK, October 6th 2026– Drug discovery teams are under pressure to evaluate more molecules, deliverresults faster and achieve more with the resources they already have. AI canhelp, but scientists do not want another standalone agent to learn, validateand govern. They need a practical way to use the AI tools they already trustwithin the scientific workflows they rely on every day.
The Flare AI Client is Cresset's answer tothat challenge.
Released as part of Flare™ V13, Cresset'splatform for molecular design, modeling and analysis, the Flare AI Clientenables researchers to use their preferred AI provider such as Claude Code or GitHubCopilot directly within Flare. Scientists can automate workflows and analyzeresults using the AI tools they already trust, helping turn hours spentoperating software into minutes of scientific review.
"The promise of AI in drug discoveryis not that it replaces scientists," said Dr Tim Cheeseright, CEO ofCresset. "It's that it removes friction from the work scientists do everyday. Whether that's exploring chemical space, generating new molecular ideas orcompleting routine modeling workflows, our goal is simple: help discovery chemistsspend less time operating software and more time making scientific decisions. Chemistsdon't need another provider. They need their time back."
While AI tools are becoming increasinglycommon across research organisations, many scientific teams struggle tointegrate them into regulated research environments and established moleculediscovery workflows. Researchers often move information between multipleapplications, manually configure calculations and repeatedly perform routinetasks that add little scientific value.
The Flare AI Client addresses thischallenge by enabling AI assistants to interact directly with Flare's moleculardesign, modeling and analysis capabilities. Using natural language, scientistscan set up and execute modeling workflows, explore molecular datasets, generatebespoke analysis scripts and automate routine reporting and data-processingtasks without leaving the platform.
Unlike standalone scientific AI agents, theFlare AI Client allows organisations to connect their existing approved AIassistants directly to Flare's computational chemistry capabilities.
"Scientists already havecompany-approved AI tools. Rather than asking them to adopt and govern anotherAI platform, we wanted to make those tools useful within new and existing molecularmodeling workflows. The goal isn't more AI. It's helping scientists get morevalue from the software and data they already use." said Dr TimCheeseright, CEO of Cresset.
Activities that previously requiredmultiple manual steps can now be initiated and managed through natural languageinteractions, making advanced computational chemistry methods more accessibleto more scientists. By reducing the effort required to run computationalchemistry workflows, the Flare AI Client enables scientists to focus on makingbetter discovery decisions.
The Flare AI Client is available now aspart of Flare V13.
About Flare™
Flare™ is Cresset's platform for moleculardesign, modeling and analysis. Used by scientists across industry and academia,Flare brings together molecular modeling, structure-based design, ligand-baseddesign, predictive analytics and visualization in a single environment tosupport molecule discovery decision-making. Flare helps researchers explorechemical space, understand structure-activity relationships and accelerate theidentification and optimisation of promising compounds.
For more information, visitcresset-group.com/flare.
About Cresset®
Cresset develops solutions that helpsscientists discover and design better drugs faster. For more than 25 years,Cresset's technology has supported researchers in understanding molecularinteractions, predicting compound behaviour and making informed discoverydecisions. Cresset's solutions are used by pharmaceutical, biotechnology,agrochemical and academic organisations worldwide to advance research fromearly discovery through lead optimization.
Headquartered in Cambridge, UK, Cressetserves customers across North America, Europe and Asia-Pacific.
For more information, visitcresset-group.com.